Biotech Values

[DewDiligence]

Given the much lower % sales dollars flowing to Momenta (than for Copaxone) apparently big pharma and Momenta either:
1) Disagree with your assertion above
OR
2) Don't think Momenta will be sole substitutible
OR
3) Don't think Momenta will get fully substitutible at all and will thus be just one of the multitudes of non-subs biosimilars.

What does the Copaxone deal have to do with any of this? Copaxone is sui generis.